novo nordisk semaglutide clinical trials AD/PD 2026: Nordisk's fails to demonstrate any benefit for early Alzheimer's evoke and evoke+: design of

Fullness and Slower Digestion: Like Tirzepatide, it slows stomach emptying and helps people eat less

Phase 2 type 2 diabetes trial findings Rosenstock and colleagues ( Lancet , 2023;402(10401):529-544) reported the Phase 2 trial of retatrutide in adults with type 2 diabetes and overweight or obesity

Eli Lilly argued that deposition testimony and post-report notes suggested plaintiffs planned to introduce previously undisclosed opinions related to gastrointestinal injuries and warning adequacy

Obesity is recognized as an illness, not a moral failing, Johnson says

46 Higher doses are more likely to provoke these adverse symptoms, indicating a dose-dependent relationship